Guido Oelkers - Swedish Orphan Insider

Swedish Orphan Biovitrum AB -- USA Stock  

USD 14.72  0.0005  0.0034%

President CEO

Mr. Guido Oelkers, Ph.D. was appointed President and Chief Executive Officer at Swedish Orphan Biovitrum AB effective as of May 22, 2017. Guido Oelkers joined Sobi from his previous role as CEO at BSN Medical GmbH. He has extensive experience from pharmaceutical and health care companies including a role as President and CEO of the Swedish medtech company Gambro, CEO of the specialty pharmaceutical company Invida and a number of executive commercial operations roles in companies such as Nycomed, DKSH Group and Aventis, where he began his career. Guido Oelkers was also a member of the Board of Directors for Meda. Guido Oelkers holds a Ph.D. in Strategic Management from the University of South Australia and a Master of Economics from South Bank University, London. He completed his postgraduate studies in Economics at London School of Economics and Political Science.
Age: 51  CEO Since 2017      
46 86 97 20 00  http://www.sobi.com

Management Efficiency

The company has return on total asset (ROA) of 5.92 % which means that it generated profit of $5.92 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 11.34 % meaning that it generated $11.34 on every $100 dollars invested by stockholders.
The company has accumulated 60.4 M in total debt with debt to equity ratio (D/E) of 8.4 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Swedish Orphan Biovitrum AB has Current Ratio of 1.69 which is within standard range for the sector.

Similar Executives

Found 4 records

CEO Since

Carl HansenAtacama Pacific Gold Corporatio
2009
Tim CookApple Inc
2011
Timothy CookApple Inc
2011
Jose LimMetro Pacific Investments Corpo
2006

Entity Summary

Swedish Orphan Biovitrum AB , an integrated biopharmaceutical company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetics and metabolism diseases primarily in Europe and North America. Swedish Orphan Biovitrum AB (BIOVF) is traded on OTC Market in USA. It is located in Stockholm, and employs 758 people.

Did you try this?

Run Portfolio Backtesting Now
   

Portfolio Backtesting

Avoid under-diversification and over-optimization by backtesting your portfolios
Hide  View All  NextLaunch Portfolio Backtesting
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Swedish Orphan Biovitrum AB to your portfolio

Top Management

Swedish Orphan Biovi Leadership Team
Hans Wigzell, Director, Ph.D
Lennart Johansson, Director, MBA
Annette Clancy, Director
Trista Morrison, President
Kirsti Gjellan, President
Jorgen Winroth, VP
Milan Zdravkovic, President, Ph.D
Hans Schikan, Director
Dennis Pedersen, President
Helena Saxon, Director, MBA
Anders Edvell, Executive, MBA
Geoffrey McDonough, CEO, Ph.D
Lars Dreioee, President, MBA
Alan Raffensperger, COO
Fredrik Berg, Executive
BoGunnar Rosenbrand, Director
Adine Axen, Director
Birgitte Volck, President
MatsOlof Wallin, President
Stefan Fraenkel, President, MBA
Hakan Bjorklund, Chairman, Ph.D
Cecilia Forberg, President
Stephen James, President, Ph.D
Bo Hansen, Chairman, Ph.D
Armin Reininger, President, Ph.D
Catarina Larsson, Director
Wills HughesWilson, President
Guido Oelkers, CEO
Jeffrey Jonas, Director, Ph.D
Matthew Gantz, Director, MBA
Theresa Heggie, Director

Stock Performance

Swedish Orphan Performance Indicators